Milestone Pharmaceuticals Announces Availability Of Nasal Spray For The Conversion Of Acute Symptomatic Episodes Of Paroxysmal Supraventricular Tachycardia Through Commercial National Formularies, Effective March 27

Benzinga Newsdesk www.benzinga.com Neutral 54.4%

Neg 0% Neu 54.4% Pos 0%

Comments

No comments yet. Be the first!